Clinical Trials - malecare.org

ASCO 2014: Combining Advanced Hormone Therapies (Zytiga & Xtandi) Shows Promise for Men with Advanced Prostate Cancer

In my continuing reports about interesting and pertinent information released at the ASCO 2014 meeting one abstract described a phase 2 trial combining an attack on androgens in metastatic prostate cancer resistant to initial hormone therapy. This proof of concept study showed that combining Enzalutamide (Xtandi) plus abiraterone (Zytiga) drove down testosterone levels and appeared [...]

By Malecare|2017-10-19T10:48:10-04:00June 5th, 2014|2nd line hormone therapy, abiraterone acetate, ADT, Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, enzalutamide, Uncategorized, Xtandi, Zytiga|1 Comment

The ASCO 2014 Game Changer – Early Chemotherapy for Some Men Extends Survival

I was asked if there was one item that was a real game changer at the American Society of Clinical Oncologists (ASCO) meeting for men with advanced prostate cancer. The answer is yes, at this meeting it was formally shown by a study that starting chemotherapy (docetaxel) along with androgen deprivation therapy (ADT) in some [...]

By Malecare|2014-06-03T10:23:15-04:00June 3rd, 2014|ADT, Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, Uncategorized, Understanding APC|4 Comments

Preliminary Data Released for A Phase II Trial of Sipuleucel-T (Provenge) with Concurrent or Sequential Enzalutamide (Xtandi) in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

There will be an abstract presented at the Upcoming (May 31- June 3) American Society of Clinical Oncologist Annual Meeting (ASCO) providing very preliminary data on a clinical trial combing Sipuleucel-T (Provenge) and enzalutamide (Xtandi) in men with metastatic castrate resistant prostate cancer (mCRPC). This rational for conducting this trial is the lack of cross [...]

By Malecare|2020-02-04T10:12:06-05:00May 16th, 2014|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, enzalutamide, immunotherapy, Provenge, Uncategorized, vaccines, Xtandi|0 Comments

A Surprising Biochemical Response to Ketoconazole In Post-Chemotherapy mCRPC Men When Compared to the Zytiga Trial Results

It has always been assumed that Ketoconazole, when used for the treatment of men with metastatic castration resistant prostate cancer (mCRPC), would not be as potent as abiraterone (Zytiga), but there has never been any head to head comparison to demonstrate this assumption! Ketoconazole is a less potent inhibitor of the CYP-17 enzyme, the mode [...]

By Malecare|2014-05-12T17:10:17-04:00May 12th, 2014|2nd line hormone therapy, Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, ketoconazole, Uncategorized, Understanding APC, Zytiga|0 Comments

Just One Year On Androgen Deprivation (ADT) Creates Significant Lipid and Glucose Metabolism Problems

It is a widely understood that androgen deprivation therapy (ADT) causes adverse side effects and events. Some researchers believe that the ADT-induced alterations in lipid and glucose metabolism may be race-dependent. To evaluate this concern the researchers recruited Japanese men with newly diagnosed prostate cancer who also underwent at least one year of ADT. They [...]

By Malecare|2017-10-19T10:48:24-04:00May 6th, 2014|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Uncategorized, Understanding APC|0 Comments